Best AI Drug Discovery Platforms 2025
Compare the leading AI-powered drug discovery companies based on benchmarks, capabilities, clinical progress, and technology approach.
Quick Summary: Best AI Drug Discovery by Use Case
GPQA Diamond Benchmark Rankings
GPQA Diamond tests AI systems on graduate-level biology, chemistry, and physics questions. It's the most relevant benchmark for evaluating AI scientific reasoning capability.
| Platform | GPQA Score | vs Human PhD (69.7%) |
|---|---|---|
| Gemini 3.1 Pro | 94.1% | +24.4 points above human expert |
| GPT-5.5 | 93.5% | +23.8 points above human expert |
| Omic AI Scientist | 93.3% | +23.6 points above human expert |
| Claude Fable 5 | 92.6% | +22.9 points above human expert |
| Human PhD Expert | 69.7% | Domain expert baseline |
Platform Comparison
| Platform | Focus | Approach | Pipeline Status |
|---|---|---|---|
| Omic | Digital patients, multi-omics, systems biology | Multi-omics integration + AI reasoning | 4 programs in lead optimization |
| Recursion | Phenomics, high-throughput imaging | Computer vision on cellular phenotypes | Multiple Phase I/II candidates |
| Insilico Medicine | Generative chemistry, aging | Generative AI for molecule design | Phase II (IPF) |
| Exscientia | Automated drug design | Active learning + human-AI collaboration | Multiple Phase I/II candidates |
| Relay Therapeutics | Protein motion dynamics | Physics-based protein simulation | Phase I/II candidates |
| Schrödinger | Physics-based simulation | Quantum mechanics + ML | Partnered programs |
Platform Profiles
Omic
Digital patients, multi-omics, systems biology
Recursion
Phenomics, high-throughput imaging
Insilico Medicine
Generative chemistry, aging
Exscientia
Automated drug design
Relay Therapeutics
Protein motion dynamics
Schrödinger
Physics-based simulation
Frequently Asked Questions
What is the best AI for drug discovery?
The best AI depends on your needs. For scientific reasoning and multi-omics, Omic scores a best-in-class 93.3% on GPQA Diamond, on par with frontier general models and far ahead of human PhD experts (69.7%). For phenotypic screening, Recursion excels. For generative chemistry, Insilico is strong. Most effective programs use multiple AI approaches.
Which AI companies have drugs in clinical trials?
Insilico Medicine has a drug in Phase II for IPF. Exscientia and Recursion have multiple Phase I/II candidates. Relay Therapeutics has Phase I/II programs in oncology. Omic has 4 programs in lead optimization.
What should I look for in an AI drug discovery platform?
Key factors: Benchmark performance (GPQA scores), therapeutic area expertise, data integration capabilities, end-to-end vs. point solution, regulatory track record, enterprise support, and pricing model.
Ready to see the leading platform in action?
Omic achieves 93.3% on GPQA Diamond, a best-in-class score in AI drug discovery. See how our digital patient platform can accelerate your programs.
Schedule Demo